Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
about
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsTreatment of diffuse large B cell lymphomaCentral nervous system prophylaxis in diffuse large B-cell lymphoma.Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.NHL (diffuse large B cell lymphoma)Central nervous system disease in hematologic malignancies: historical perspective and practical applications.High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.NHL (diffuse large B-cell lymphoma).[Visualization of radiation effects on the central nervous system].High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone.Peripheral T-cell lymphoma: review and updates of current management strategiesIdentification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsIsolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisSurvival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaA Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.Central nervous system-directed preventative therapy in adults with lymphoma.Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.The therapeutic use of rituximab in non-Hodgkin's lymphoma.Modern management of non-Hodgkin lymphoma in HIV-infected patients.Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms.Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.New Challenges in the Management of Diffuse Large B-Cell Lymphoma.The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era.Current treatment approaches for diffuse large B-cell lymphoma.Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphomaSecondary lymphomas of the central nervous system: risk, prophylaxis and treatment.Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).Unresolved issues in diffuse large B-cell lymphomas.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.
P2860
Q24242089-7AAA7324-3DEA-4981-8BCA-05E67B85F36FQ27006062-1D1FDFDE-7B35-4DC3-8DAD-BC59E8403E62Q30251550-C1503F7D-4C5C-4FCE-B0DF-306B78FD90A6Q31072157-0BFFB394-1BE6-4E74-A216-1FD5553470ACQ33375173-4E67EE2A-7051-4AD2-AE1F-54F6B165D4B9Q33394912-9E1B661A-87CF-40D2-AA8E-A06F626CE496Q33396261-779C370B-8047-42D7-AFEC-500C3DDC58C5Q33446735-28EC2126-CAC6-4E13-BD94-CF44E7F681E1Q33585849-63D9CAEE-966E-4E74-9F43-992C95F28168Q33626490-17CBE892-4E8B-4097-8B49-6FC896824F7FQ33828585-20196ADB-D952-473A-BCF9-6D4E9C85A39DQ33846734-0537CDB1-0F46-4A53-A5DD-74EE50470268Q34220560-46FE569F-E3EC-40A9-8291-6E066084DE89Q34228365-10A9E587-7955-4190-B8C4-A800FC2FD29AQ34479082-17265FE8-3632-47A9-8009-5DFAFF60052CQ35004750-62BA4F5F-1441-4D96-B34E-F71E7FB3040CQ35055829-8D1C4BF3-1065-450A-A73E-DDB62EB8D1E1Q35143471-4560B122-5DE0-4037-BB45-F48FCC0CB692Q35678403-88BA951A-1449-41EF-9852-2AD6B0944A5AQ35930640-46B1E1B2-79E0-4497-AE31-A99394319A31Q36262219-431A7FE6-56DF-4B39-A0E4-342AC1F80260Q36273509-60446AB4-8B28-4DB8-843C-457A85F507C6Q36407441-A3D00D23-C457-4D25-A50D-4FB4F75F1986Q36591293-FC2DB06A-B66A-43FD-8034-9D0652BD532BQ36700912-BCBF5882-3FB1-4A3B-8101-D40BC231850AQ36710347-B053C58D-1F37-4178-8B95-8D70EFFDF090Q36710973-E102F120-0FF4-4BD8-BB2A-9CD27F23AC2AQ36872779-54415045-F2BB-4EB0-8B75-2E39B7228EE1Q36934293-5B789264-3BFD-4D99-9419-95B55784B6B2Q36949764-CDB34ADE-4598-4FE6-A58B-849AF79FE4B3Q36996280-DA7A8965-EE63-4C62-94C6-D3FC3A6C687CQ37132898-D56453B4-CA62-439C-BCA0-21398F4E3977Q37136999-5FE953FF-E182-470B-B29F-3E017B9EEF22Q37212614-88313D04-56CC-45F0-A31E-931C2BEE82E5Q37280933-8C18262B-975A-4D03-8F8B-A5BD5294F2D7Q37618814-98DB6626-FB29-413D-B899-5FB0E9AE36B3Q37705417-389C8DCA-1BF7-42B5-8152-ABBD417B7908Q37863688-F65DF301-7197-4927-AB4A-BB7402B9F20FQ37934960-73836B7C-4596-493D-91E4-326BB67C20C5Q37956318-EC3BFAF9-DD3C-495C-BE68-B2E1C0A49559
P2860
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Intensive conventional chemoth ...... gressive non-Hodgkin lymphoma.
@en
Intensive conventional chemotherapy
@nl
type
label
Intensive conventional chemoth ...... gressive non-Hodgkin lymphoma.
@en
Intensive conventional chemotherapy
@nl
prefLabel
Intensive conventional chemoth ...... gressive non-Hodgkin lymphoma.
@en
Intensive conventional chemotherapy
@nl
P2093
P50
P1433
P1476
Intensive conventional chemoth ...... ggressive non-Hodgkin lymphoma
@en
P2093
Andre Bosly
Bertrand Coiffier
Christian Gisselbrecht
Eric Lepage
Felix Reyes
Georges Fillet
Groupe d'Etude des Lymphomes de l'Adulte
Herve Tilly
Michel Attal
Michel Blanc
P304
P356
10.1182/BLOOD-2003-02-0542
P407
P577
2003-08-14T00:00:00Z